AR042109A1 - Derivados de acido mandelico, procedimiento de preparacion, composicion farmaceutica que lo comprende, y, usos - Google Patents

Derivados de acido mandelico, procedimiento de preparacion, composicion farmaceutica que lo comprende, y, usos

Info

Publication number
AR042109A1
AR042109A1 ARP030104302A ARP030104302A AR042109A1 AR 042109 A1 AR042109 A1 AR 042109A1 AR P030104302 A ARP030104302 A AR P030104302A AR P030104302 A ARP030104302 A AR P030104302A AR 042109 A1 AR042109 A1 AR 042109A1
Authority
AR
Argentina
Prior art keywords
alkoxy
carbonyl
lower alkyl
amino
alkyl
Prior art date
Application number
ARP030104302A
Other languages
English (en)
Inventor
Christoph Martin Stahl
David William Banner
Luca Claudio Gobbi
Zbinden Katrin Groebke
Ulrike Obst
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR042109A1 publication Critical patent/AR042109A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente se refiere a derivados de ácido mandélico de la fórmula (1), así como a las sales fisiológicamente aceptables de los mismos. Estos compuestos inhiben la formación de los factores de coagulación Xa, IXa y trombina inducida por el factor VIIa y el factor hístico y pueden utilizarse como medicamentos. Reivindicación 1: Compuestos de la fórmula (1) en la que R1 es H, -OH, -NH2, (alcoxi inferior)-carbonilo, aril-(alcoxi inferior)-carbonilo, ariloxi-carbonilo, (alquilo inferior)-carbonilo, aril-carbonilo o (alcoxi inferior)-carbonilo que está sustituido por halógeno; R2, R3, y R4 con independencia entre sí se eligen entre H, halógeno, hidroxi, y alcoxi inferior; cuyo alcoxi inferior puede estar sustituido opcionalmente por hidroxi, carboxi o carbamoilo; R5 es alquilo inferior o cicloalquilo o, si X es O o NR12, R5 puede ser también H; R6 es H, alquilo inferior o flúor-alquilo inferior; Y es N o C-R11; R7, R8, R9, R10 y R11 con independencia entre sí se eligen entre H, hidroxi, halógeno, amino, (alquilo inferior)-amino, di-(alquilo inferior)-amino, (alquilo inferior)-carbonil-amino, NO2, flúor-alquilo inferior, alcoxi inferior, hidroxi-alcoxi inferior, flúor-alcoxi inferior, alquinilo inferior, hidroxi-alquinilo inferior, arilo, aril-alcoxi inferior, ariloxi, ariloxi-alcoxi inferior, heterociclilo, heterocicliloxi, (alcoxi inferior)-carbonil-alcoxi inferior, carbamoil-alcoxi inferior, carboxi-alcoxi inferior, cicloalquiloxi, heteroarilo, amino-alcoxi inferior, (alquilo inferior)-amino-alcoxi inferior y di-(alquilo inferior)-amino-alcoxi inferior; o R8 y R9 o R8 y R7 están unidos entre sí para formar un anillo junto con los átomos de C a los que están unidos y R8 y R9 juntos o R8 y R7 juntos son -O-CH2-O-, -O-CH2-CO-NH-, -O-CH2-CH2-CH2- o -CH=CH-CH=CH-, que pueden estar eventualmente sustituidos por alquilo inferior o alcoxi inferior y R10, R11 y R7 o R9 tienen respectivamente los significados definidos anteriormente; X es O, S, NR12 o SO2; R12 es H, alquilo inferior o (alquilo inferior)-carbonilo; y las sales farmacéuticamente aceptables de los mismos. Reivindicación 37: El uso de los compuestos según una cualquiera de las reivindicaciones 1-26 para la fabricación de medicamentos destinados al tratamiento terapéutico y/o profiláctico de trombosis arteriales y venosas, trombosis de venas profundas, embolia pulmonar, angina de pecho inestable, infarto cardíaco, apoplejía debida a fibrilación atrial, inflamación, arteriosclerosis y/o tumores.
ARP030104302A 2002-11-25 2003-11-21 Derivados de acido mandelico, procedimiento de preparacion, composicion farmaceutica que lo comprende, y, usos AR042109A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026365 2002-11-25

Publications (1)

Publication Number Publication Date
AR042109A1 true AR042109A1 (es) 2005-06-08

Family

ID=32337999

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104302A AR042109A1 (es) 2002-11-25 2003-11-21 Derivados de acido mandelico, procedimiento de preparacion, composicion farmaceutica que lo comprende, y, usos

Country Status (24)

Country Link
US (1) US7129238B2 (es)
EP (1) EP1567498B1 (es)
JP (1) JP4271657B2 (es)
KR (1) KR100705156B1 (es)
CN (1) CN1714079A (es)
AR (1) AR042109A1 (es)
AT (1) ATE384696T1 (es)
AU (1) AU2003292072B2 (es)
BR (1) BR0316508A (es)
CA (1) CA2505542A1 (es)
CO (1) CO5570663A2 (es)
DE (1) DE60318890T2 (es)
ES (1) ES2298583T3 (es)
GT (1) GT200300252A (es)
MX (1) MXPA05005446A (es)
NO (1) NO20052311L (es)
PA (1) PA8589201A1 (es)
PE (1) PE20040696A1 (es)
PL (1) PL377511A1 (es)
RU (1) RU2005120146A (es)
TW (1) TW200410921A (es)
UY (1) UY28090A1 (es)
WO (1) WO2004048335A2 (es)
ZA (1) ZA200503989B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200410921A (en) 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
US7056932B2 (en) 2003-12-19 2006-06-06 Hoffman-La Roche Inc. Heterocyclyl substituted 1-alkoxy acetic acid amides
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
RU2007112688A (ru) * 2004-09-06 2008-10-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 4-аминометилбензамина и их применение в качестве ингибиторов фактора viia
WO2007016358A1 (en) * 2005-08-02 2007-02-08 Merck & Co., Inc. N-(pyridin-4-yl)-2-phenylbutanamides as androgen receptor modulators
CN103641776A (zh) * 2007-04-24 2014-03-19 日本曹达株式会社 N-亚甲基取代甲胺多聚物的制造方法和三嗪衍生物
CN104370804A (zh) * 2007-04-24 2015-02-25 日本曹达株式会社 取代甲胺化合物的制造方法
KR101682339B1 (ko) 2007-04-24 2016-12-02 닛뽕소다 가부시키가이샤 치환 메틸아민 화합물의 제조방법 및 트리아진 유도체
US8217064B2 (en) * 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2010022148A1 (en) * 2008-08-19 2010-02-25 The Trustees Of The University Of Pennsylvania Methods for the preparation of irciniastatin and analogs thereof
EP2272661A1 (en) * 2009-07-10 2011-01-12 Amcor Flexibles Transpac N.V. Packaging material with integrated pressure relief valve
US8343970B2 (en) 2010-03-12 2013-01-01 Omeros Corporation PDE10 inhibitors and related compositions and methods
GB201006042D0 (en) 2010-04-12 2010-05-26 Givaudan Sa Improvements in or relating to organic compounds
EP2578573A4 (en) 2010-05-24 2014-08-06 Toa Eiyo Ltd CONDENSATE IMIDAZOLE DERIVATIVE
CN103044176A (zh) * 2012-12-12 2013-04-17 云南民族大学 一种氢气参与环醚开环制备卤代醇的高效方法
EP2931707A4 (en) * 2012-12-13 2016-07-20 Glaxosmithkline Llc AMPLIFIER OF ZEST HOMOLOG 2 INHIBITORS
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
MY165587A (en) 2014-07-29 2018-04-06 Evonik Degussa Gmbh Process for the epoxidation of an olefin
EP3285760A4 (en) 2015-04-24 2018-09-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
MY165609A (en) 2015-04-28 2018-04-16 Evonik Degussa Gmbh Process for the epoxidation of propene
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
JP6824269B2 (ja) 2015-11-25 2021-02-03 エボニック オペレーションズ ゲーエムベーハー プロペンおよび過酸化水素から１，２−プロパンジオールを製造するための方法
CN108430983B (zh) 2015-11-26 2022-02-22 赢创运营有限公司 用于丙烯的环氧化的方法和反应器
EP3380458B1 (en) 2015-11-26 2019-07-24 Evonik Degussa GmbH Process for the epoxidation of propene
TWI707847B (zh) 2015-11-26 2020-10-21 德商贏創運營有限公司 丙烯之環氧化方法
EA033968B1 (ru) 2015-11-26 2019-12-16 Эвоник Дегусса Гмбх Способ эпоксидирования олефина
HUE050560T2 (hu) 2016-01-19 2020-12-28 Evonik Operations Gmbh Eljárás olefin epoxidálására
EA035906B1 (ru) 2016-03-21 2020-08-28 Эвоник Оперейшнс Гмбх Способ эпоксидирования пропилена
EP3246323A1 (en) 2016-05-17 2017-11-22 Evonik Degussa GmbH Integrated process for making propene oxide from propane
WO2018205244A1 (en) 2017-05-12 2018-11-15 Evonik Degussa Gmbh Process for the epoxidation of propene
EP3406603A1 (en) 2017-05-22 2018-11-28 Evonik Degussa GmbH Process for the epoxidation of propene
EP3438101A1 (en) 2017-08-01 2019-02-06 Evonik Degussa GmbH Process for the epoxidation of propene
AU2021290173A1 (en) * 2020-06-10 2023-02-09 Cyxone Ab Rabeximod in the treatment of rheumatoid arthritis
KR20240006545A (ko) 2021-05-10 2024-01-15 에보닉 오퍼레이션스 게엠베하 프로펜 옥사이드를 제조하기 위한 통합 플랜트 및 통합 프로세스

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128681A1 (de) * 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
PT921116E (pt) * 1997-12-04 2003-11-28 Hoffmann La Roche Derivados de n-(4-carbamimido-fenil)-glicinamida
EP1078917A4 (en) * 1998-02-17 2002-11-06 Ono Pharmaceutical Co AMIDINO DERIVATIVES FOR USE AS ACTIVE INGREDIENTS AND MEDICINES CONTAINING THEM
WO2000035858A1 (en) * 1998-12-14 2000-06-22 F. Hoffmann-La Roche Ag Phenylglycine derivatives
US6852761B2 (en) * 2000-03-13 2005-02-08 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6548694B2 (en) * 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
DE10027024A1 (de) * 2000-05-31 2001-12-06 Merck Patent Gmbh Carbaminsäureester
DE10037146A1 (de) * 2000-07-29 2002-02-07 Merck Patent Gmbh Acetamidderivate
DE10040783A1 (de) * 2000-08-21 2002-03-07 Merck Patent Gmbh AZA-Aminosäurederivate (Faktor X¶a¶-Inhibitoren 15)
EP1193248A1 (en) * 2000-09-30 2002-04-03 Aventis Pharma Deutschland GmbH Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use
DK1383731T3 (da) * 2000-10-20 2009-12-07 Biocryst Pharm Inc Biarylforbindelser som serinproteaseinhibitorer
AU2002231235A1 (en) * 2000-11-07 2002-05-21 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
EP1364960A4 (en) * 2001-02-02 2005-05-18 Chugai Pharmaceutical Co Ltd PEPTIDE DERIVATIVES
GB0121337D0 (en) * 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
TW200410921A (en) 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives

Also Published As

Publication number Publication date
ATE384696T1 (de) 2008-02-15
WO2004048335A3 (en) 2004-08-19
JP2006515284A (ja) 2006-05-25
EP1567498B1 (en) 2008-01-23
GT200300252A (es) 2004-06-28
NO20052311L (no) 2005-06-16
US20040122057A1 (en) 2004-06-24
US7129238B2 (en) 2006-10-31
CA2505542A1 (en) 2004-06-10
MXPA05005446A (es) 2005-08-26
BR0316508A (pt) 2005-10-04
ES2298583T3 (es) 2008-05-16
EP1567498A2 (en) 2005-08-31
ZA200503989B (en) 2006-12-27
AU2003292072A1 (en) 2004-06-18
PL377511A1 (pl) 2006-02-06
PE20040696A1 (es) 2004-10-08
UY28090A1 (es) 2004-05-31
WO2004048335A2 (en) 2004-06-10
PA8589201A1 (es) 2004-07-26
CN1714079A (zh) 2005-12-28
TW200410921A (en) 2004-07-01
KR20050086774A (ko) 2005-08-30
AU2003292072B2 (en) 2006-12-07
DE60318890D1 (de) 2008-03-13
DE60318890T2 (de) 2009-01-15
CO5570663A2 (es) 2005-10-31
KR100705156B1 (ko) 2007-04-09
RU2005120146A (ru) 2006-05-10
JP4271657B2 (ja) 2009-06-03

Similar Documents

Publication Publication Date Title
AR042109A1 (es) Derivados de acido mandelico, procedimiento de preparacion, composicion farmaceutica que lo comprende, y, usos
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
AR033306A1 (es) Compuestos
AR039127A1 (es) Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
HUP0300894A2 (hu) Szubsztituált béta-karbolinok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CL2004000174A1 (es) Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer.
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
DE60141849D1 (de) Pharmazeutisch aktive sulfonamid-derivate
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
CY1110395T1 (el) Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
AR036101A1 (es) Derivados naftil indol sustituidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento como inhibidores del inhibidor de tipo -1 activador de plasminogeno (pai-1)
RU2006130000A (ru) Органические соединения
AR035430A1 (es) Indanil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
BR0110112A (pt) Derivados de pirrolidina e piperidina e seu uso para o tratamento de distúrbios neurodegenerativos
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
AR116474A1 (es) DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV
AR115303A1 (es) Moduladores de calpaína y usos terapéuticos de los mismos
AR040246A1 (es) Derivados de 1-piperazinilacilpiperidina substituidos, su preparacion y su aplicacion en terapeutica
AR055384A1 (es) Derivados de indol
AR036649A1 (es) Derivados de diarilmetilen piperidina, uso de estos derivados para la manufactura de medicamentos y composicion farmaceutica
SE0102440D0 (sv) New compound

Legal Events

Date Code Title Description
FA Abandonment or withdrawal